Related references
Note: Only part of the references are listed.Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis
Maxim Grymonprez et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis
Sittinun Thangjui et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
Jeffrey S. Berger et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
Jan Steffel et al.
EUROPACE (2021)
Food-related impulsivity assessed by longitudinal laboratory tasks is reduced in patients with binge eating disorder in a randomized controlled trial
Kathrin Schag et al.
SCIENTIFIC REPORTS (2021)
World Heart Federation Roadmap on Atrial Fibrillation - A 2020 Update
Ben Freedman et al.
GLOBAL HEART (2021)
Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories
Amr F. Barakat et al.
JACC-CLINICAL ELECTROPHYSIOLOGY (2021)
Obesity and Stroke: Does the Paradox Apply for Stroke?
Gabriel A. Quinones-Ossa et al.
NEUROINTERVENTION (2021)
Obesity paradox and stroke: a narrative review
Stefano Forlivesi et al.
EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY (2021)
Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis
Yue Zhou et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2020)
Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship with Oral Anticoagulant Drugs
Marco Proietti et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2020)
Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis
Aaqib H. Malik et al.
EUROPACE (2020)
Use of Direct Oral Anticoagulants in Morbidly Obese Patients
Kazuhiko Kido et al.
PHARMACOTHERAPY (2020)
Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients
Stephen Y. Wang et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial
Michel Zeitouni et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study
Steve Deitelzweig et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Epidemiology of Atrial Fibrillation in the 21st Century Novel Methods and New Insights
Jelena Kornej et al.
CIRCULATION RESEARCH (2020)
Network Meta-Analysis Comparing Apixaban Versus Rivaroxaban in Morbidly Obese Patients With Atrial Fibrillation
Kazuhiko Kido et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects
Mohammed Bouhajib et al.
DRUG RESEARCH (2020)
Heart Disease and Stroke Statistics-2019 Update A Report From the American Heart Association
Emelia J. Benjamin et al.
CIRCULATION (2019)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Craig T. January et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
A comprehensive diagnostic approach to detect underlying causes of obesity in adults
Eline S. van der Valk et al.
OBESITY REVIEWS (2019)
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Wonkyung Byon et al.
CLINICAL PHARMACOKINETICS (2019)
Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project
Antonio Di Carlo et al.
EUROPACE (2019)
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight Insights From the ARISTOTLE Trial
Stefan H. Hohnloser et al.
CIRCULATION (2019)
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
Giuseppe Boriani et al.
EUROPEAN HEART JOURNAL (2019)
Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients
Bhradeev Sivasambu et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2018)
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis
Bianca Rocca et al.
EUROPEAN HEART JOURNAL (2018)
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
Michael D. Ezekowitz et al.
EUROPEAN HEART JOURNAL (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases
Andrew Elagizi et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2018)
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
Stefan Willmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities
Courtney McCuen-Wurst et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2018)
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study
Siavash Piran et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives
Federico Nardi et al.
EUROPEAN HEART JOURNAL SUPPLEMENTS (2017)
Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies
Dagfinn Aune et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2017)
Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulant Trials
Marco Proietti et al.
STROKE (2017)
Drug dosing in obese adults
Michael Barras et al.
AUSTRALIAN PRESCRIBER (2017)
The impact of body weight on rivaroxaban pharmacokinetics
Sarah J. Barsam et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)
Somasekhara R. Balla et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
Dolly A. Parasrampuria et al.
CLINICAL PHARMACOKINETICS (2016)
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
Roopinder K. Sandhu et al.
EUROPEAN HEART JOURNAL (2016)
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K. Martin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
Andreas Goette et al.
LANCET (2016)
Body Mass Index, the Most Widely Used But Also Widely Criticized Index: Would a Criterion Standard Measure of Total Body Fat Be a Better Predictor of Cardiovascular Disease Mortality?
Francisco B. Ortega et al.
MAYO CLINIC PROCEEDINGS (2016)
Real-world variability in dabigatran levels in patients with atrial fibrillation: reply
N. C. Chan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections
Eyob D. Adane et al.
PHARMACOTHERAPY (2015)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2014)
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation
Riccardo Cappato et al.
EUROPEAN HEART JOURNAL (2014)
Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the US Adult Population
Susan Colilla et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Vijay V. Upreti et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects
M. Ulvestad et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060
Bouwe P. Krijthe et al.
EUROPEAN HEART JOURNAL (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors
Tatiana F. S. Teixeira et al.
CLINICAL NUTRITION (2012)
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
Paulus Kirchhof et al.
EUROPACE (2012)
Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients
Simone van Kralingen et al.
CLINICAL PHARMACOKINETICS (2011)
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
K-H Liesenfeld et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Michael J. Hanley et al.
CLINICAL PHARMACOKINETICS (2010)
The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation The WHS (Women's Health Study)
Usha B. Tedrow et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The link between abdominal obesity, metabolic syndrome and cardiovascular disease
S. A. Ritchie et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2007)
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Systematic overview of warfarin and its drug and food interactions
AM Holbrook et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Alterations of gastrointestinal motility in obesity
JH Xing et al.
OBESITY RESEARCH (2004)
Glomerular hemodynamics in severe obesity
A Chagnac et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2000)
Share Paper
